News

89bio: Promising As Pegozafermin Nears Phase 3 Readout
Pegozafermin, ETNB's FGF21 analog, shows promise in late-stage trials for MASH & severe hypertriglyceridemia. Key data & ...
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the ...
Painkiller taken by millions could trigger deadly heart failure – are you in the at-risk groups?
A POPULAR medication used to treat chronic nerve pain, anxiety and epilepsy has been linked to a significantly increased risk of heart failure. Doctors have been urged to exercise caution when ...
pharmaphorum4h
Mind the gap: The need for gender-specific outcome measurement
One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...